Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
This study is recruiting at 45 US sites in 24 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- NSCLC (Non-small Cell Lung Cancer)
- Non-Small Cell Lung Cancer
- NSCLC
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC (Advanced Non-small Cell Lung Cancer)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Alabama Oncology · Birmingham, AL
California · 1
- MemorialCare Long Beach Medical Center · Long Beach, CA
Connecticut · 1
- Yale University, Smillow Cancer Center · New Haven, CT
Florida · 6
- Florida Cancer Specialists & Research Institute - South · Fort Myers, FL
- BRCR Global · Plantation, FL
- Cancer Care Centers of Breevard · Rockledge, FL
- Florida Cancer Specialists & Research Institute - North · St. Petersburg, FL
- Cleveland Clinic Martin North · Stuart, FL
- Florida Cancer Specialists & Research Institute - East · West Palm Beach, FL
Georgia · 3
- University Cancer and Blood Center · Athens, GA
- Piedmont Healthcare, Inc · Atlanta, GA
- Winship Cancer Institute · Atlanta, GA
Illinois · 2
- Center for Care and Discovery · Chicago, IL
- University of Illinois Cancer Center · Chicago, IL
Iowa · 3
- University of Iowa Health Care Cancer Services Quad Cities · Bettendorf, IA
- University of Iowa Hospitals & Clinics · Iowa City, IA
- University of Iowa Health Care, Mission Cancer + Blood · Waukee, IA
Kansas · 1
- The University of Kansas Cancer Center · Westwood, KS
Maryland · 1
- Johns Hopkins University of Medicine · Baltimore, MD
Michigan · 3
- Trinity Health Ann Arbor Hospital · Ann Arbor, MI
- Henry Ford Health · Detroit, MI
- Karmanos Cancer Institute · Detroit, MI
Missouri · 1
- Washington University School of Medicine - Siteman Cancer Center · St Louis, MO
Montana · 1
- St. Vincent Frontier Cancer Center · Billings, MT
New Hampshire · 1
- Dartmouth-Hitchcock Medical Center · Lebanon, NH
New Jersey · 2
- John Theurer Cancer Center at Hackensack UMC · Hackensack, NJ
- Morristown Medical Center (MMCORC) · Morristown, NJ
New York · 3
- Roswell Park Cancer Institute · Buffalo, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- Montefiore Medical Center · The Bronx, NY
North Carolina · 1
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina · Chapel Hill, NC
Ohio · 2
- TriHealth Cancer & Blood Institute Research · Cincinnati, OH
- Taylor Cancer Research Center · Maumee, OH
Oregon · 1
- Oncology Associates of Oregon PC · Eugene, OR
Pennsylvania · 1
- Penn State Milton S. Hershey Medical Center · Hershey, PA
South Dakota · 2
- Avera Saint Luke's Hospital · Aberdeen, SD
- Avera Cancer Institute · Sioux Falls, SD
Tennessee · 1
- SCRI Oncology Partners - Tennessee · Nashville, TN
Texas · 4
- Texas Oncology - South Austin · Austin, TX
- Texas Oncology Dallas · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
- Texas Oncology - Gulf Coast · The Woodlands, TX
Utah · 2
- Huntsman Cancer Institute · Salt Lake City, UT
- Utah Cancer Specialists · Salt Lake City, UT
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.